TY - JOUR
T1 - Pharmacotherapy for obesity
AU - Neff, Lisa M.
AU - Aronne, Louis J.
N1 - Funding Information:
Dr. Aronne has received financial support for research from Amylin, Sanofi-Aventis, Pfizer, Transneuronix, Medtronic, Merck, Obecure, and Orexigen. He is a consultant for GlaxoSmithKline, Sanofi-Aventis, Metabolic Therapeutics, and Manhattan Pharmaceuticals, and he is a member of the Speakers’ Bureau for Pfizer and Sanofi-Aventis. Dr. Arrone can be contacted at the Weill Medical College of Cornell University in New York, NY.
PY - 2007/12
Y1 - 2007/12
N2 - Obesity is a chronic metabolic disorder that affects one third of American adults. Modest weight losses of just 5% to 10% of body weight, which are achievable with lifestyle modification and pharmacotherapy, can lead to remarkable improvements in many obesity-associated co-morbidities, including dyslipidemia, hypertension, and type 2 diabetes. In this review, the indications for pharmacotherapy and the goals of treatment are discussed, and current and future pharmacologic approaches to the treatment of obesity are examined. Current pharmacologic therapies for obesity are limited, but recent advances in our understanding of the complex and overlapping endocrine pathways that regulate body weight have led to new opportunities for antiobesity drug development. Important drug targets that are highlighted in this review include adipocyte-derived hormones, hypothalamic neuropeptides, and gastrointestinal hormones.
AB - Obesity is a chronic metabolic disorder that affects one third of American adults. Modest weight losses of just 5% to 10% of body weight, which are achievable with lifestyle modification and pharmacotherapy, can lead to remarkable improvements in many obesity-associated co-morbidities, including dyslipidemia, hypertension, and type 2 diabetes. In this review, the indications for pharmacotherapy and the goals of treatment are discussed, and current and future pharmacologic approaches to the treatment of obesity are examined. Current pharmacologic therapies for obesity are limited, but recent advances in our understanding of the complex and overlapping endocrine pathways that regulate body weight have led to new opportunities for antiobesity drug development. Important drug targets that are highlighted in this review include adipocyte-derived hormones, hypothalamic neuropeptides, and gastrointestinal hormones.
UR - http://www.scopus.com/inward/record.url?scp=38149074636&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38149074636&partnerID=8YFLogxK
U2 - 10.1007/s11883-007-0061-0
DO - 10.1007/s11883-007-0061-0
M3 - Review article
C2 - 18377785
AN - SCOPUS:38149074636
SN - 1523-3804
VL - 9
SP - 454
EP - 462
JO - Current atherosclerosis reports
JF - Current atherosclerosis reports
IS - 6
ER -
